Tag: lsd

LSD And Psilocybin Could Be Powerful Treatments For Pain—Without Opioids’ Dwindling Effects Over Time, Study Says

LSD and psilocybin could offer promising therapeutic potential for the treatment of chronic pain “on a mechanistic and experiential level,” according to a newly published literature review that highlights scientific findings happening as part of the “psychedelic renaissance”—a recent thawing of stigma and opposition into psychedelics research after decades of prohibition.

What’s more, authors note, the pain-relieving effects of LSD and psilocybin seem to increase with repeated treatment, unlike opioids, which display “decreased therapeutic effect” over time.

The narrative review, published last month in the South African Medical Journal, charts both the history of the two substances as well as scientists’ emerging understanding of their methods of action. It notes that the drugs seem not just to reduce pain but also better manage the experience of pain.

“Recent neuroimaging studies combined with small sample interventions with classic psychedelic agents,” authors wrote, “may point towards a possible means of improving the treatment of chronic pain on a mechanistic and experiential level.”

Classic psychedelics, the literature review explains, are those that bind to the central nervous system’s 5-HT2A receptors. They include both LSD and psilocybin.

The way psilocybin binds to receptors in the central nervous system “has similar effects to LSD on cognition, emotional processing, self-awareness and the perception of pain,” says the literature review, “which underpins its potential therapeutic benefit in treating people suffering with pain. Numerous small trials of LSD and psilocybin for chronic pain have already shown a good safety profile, with minimal physical dependence, withdrawal syndrome, or compulsive drug seeking compared with other analgesic agents.”

While the two drugs are part of the same family of alkaloids, their history is, of course, much different. The review describes explains that LSD was first synthesized in 1938, meaning humans have used it for less than a century. Psilocybin’s use stretches back thousands of years. In the modern U.S., psilocybin use was popularized in the late 1950s, while LSD grew to prominence in the ’60s and ’70s.

While there have been no reports of direct mortality from either substance and no withdrawal following chronic use, the study says, “the use of psilocybin in clinical research ended at the same time as LSD research as the Controlled Substances Act was enforced.”

Associations with counterculture and anti-government sentiment meant LSD and psilocybin research was abandoned, authors wrote. “From 1977 until the early 2000s, no more LSD research was published, despite overwhelming evidence pointing towards therapeutic benefit.”

Prior research had indicated LSD might be useful in treating depression, pain, and physical suffering in cancer patients and others. Among seven patients with phantom limb pain, participants treated with LSD reduced their analgesic requirements, and two patients’ pain was resolved.

During what the review refers to as the modern “psychedelic renaissance” or “the new wave of psychedelic research,” studies have found that psilocybin or LSD may help reduce cluster headaches, end-of-life depression in cancer patients and chronic pain.

In a pain study, a small sample of patients who self-medicate with the psychedelics “revealed a decrease in the experience of pain during the psychedelic session and for up to 5 days after treatment, before their pain returned to baseline.”

“The most exciting revelation from these interviews relates to the lasting psychological and emotional effect the psychedelics had on those interviewed,” the review says. “They describe increased resilience, body-self-awareness and psychological flexibility and psychological flexibility, which led to feelings of acceptance, agency and hope.”

Keep reading

Did a dose of LSD spawn some of cinema’s greatest films?

Federico Fellini, one of the greatest filmmakers of the 20th century, attributes much of his success to a single dose of LSD he took in the summer of 1964 ​“during a time of creative crisis”. According to a recent study looking into how this experience influenced his work, the dose was administered by Dr Emilio Servadio, one of the most prominent Italian psychoanalysts of the time. It induced a trip so intense that the filmmaker later needed sedative medication to put it to an end.

Fellini took part in the psychotherapy session directly after he had finished working on his masterpiece 8 ½, and before he started writing his next film Giulietta degli Spiriti. The talking therapy that occurred after the LSD dose was recorded with a magnetophone. The tapes have never been found by researchers, but in an interview with the BBC a year later, Fellini explained how the experience stimulated his creativity by altering his perception of colour and allowing him to perceive colours in an entirely different light.

“The doctor gave me an explanation and I agree with him,” he told a reporter in 1965. ​“He said that an artist lives always in the imagination so the barrier between sensorial reality and his imagination is very vague… I saw colours not like they normally are – we see colours in the objects, you know; we see objects that are coloured. I saw colours detached from the objects. I had for the first time the feeling of the presence of the colours in a detached way.” Fellini’s work after the acid trip was later praised for having ​“supernaturally brilliant colours”.

Fellini’s perception of time was also altered during his trip, which was was reflected in his work post-LSD trip – the authors of the study said his films started to incorporate plots involving ​“puzzling and disorienting flashbacks”. The filmmaker was also said to have had epiphanies during the trip involving space and perception of self, both of which were apparent in his subsequent work. ​“The world depicted in his post-LSD movies includes major changes in the perception of space, time and others,” the study concluded.

Keep reading

FDA creates path for psychedelic drug trials

Federal regulators are laying out guidance for psychedelic drug trials for the first time, in a move that could encourage the mainstreaming of substances like magic mushrooms and LSD as behavioral health treatments.

Why it matters: Psychedelics are turning into a multi-billion industry and gaining widespread acceptance after decades of concerns about recreational use of the products — and the high risk for misuse. But research to date has largely been backed by private sponsors.

Driving the news: The Food and Drug Administration on Friday released first-ever draft guidance outlining considerations — including trial conduct, data collection and subject safety — for researchers looking into psychedelic treatments for a variety of conditions, including PTSD, depression and anxiety.

  • The agency filed the 14-page document two days after a bipartisan coalition in Congress led by Rep. Dan Crenshaw (R-Texas) introduced legislation directing the issuance of clinical trial guidelines.
  • It also came as 10,000 attendees and hundreds of exhibitors converged on Denver for what was billed as the “largest psychedelic conference in history,” with guests ranging from New York Jets quarterback Aaron Rodgers to National Institute of Mental Health director Joshua Gordon.

Keep reading

Psychedelic drugs like LSD could enhance the effects of brain simulation

New research provides evidence that LSD alters the effects of brain stimulation and produces different and potentially larger changes in brain activity. The preliminary findings suggest that psychedelic drugs and brain stimulation may have a synergistic effect that could be used in innovative ways for treating various conditions. The proof-of-concept study has been published in the journal Psychedelic Medicine.

Psychedelic-assisted psychotherapy has shown promising potential as a therapeutic approach for various mental health conditions. This treatment combines the use of psychedelic substances, such as psilocybin or LSD, with psychotherapy sessions to enhance the therapeutic process.

The psychedelic substances used in this type of therapy are known to induce altered states of consciousness, leading to profound experiences that can have therapeutic benefits. These substances are thought to work by affecting brain receptors, particularly the serotonin 2A receptor, which influences perception, mood, and cognition.

These drugs have also been found to enhance neural plasticity, which refers to the brain’s ability to reorganize and form new connections. This may contribute to their long-term therapeutic effects. It is believed that combining psychedelic drugs with therapies like psychotherapy or brain stimulation could help direct these neuroplastic changes and lead to lasting behavioral changes.

“Current treatments like transcranial magnetic stimulation (TMS) have a large potential to help people with a variety of psychiatry disorders, however, these neuromodulatory treatments tend to have relatively short-lived effects,” explained study author Lucas Dwiel, a postdoctoral fellow at The Doucette Lab at the Geisel School of Medicine at Dartmouth. “So if we could prolong the effects of these treatments by first using drugs like LSD to make the brain more malleable or susceptible to change, we could help a large number of patients achieve their therapeutic goals.”

The researchers conducted experiments using rats to eliminate the biases inherent in human studies. The study focused on the effects of LSD and involved two main components: measuring brain activity changes after LSD administration and assessing the effects of brain stimulation combined with LSD.

Keep reading

LSD and Magic Mushrooms Dramatically Rewire the Brain, New Study Reveals

From ketamine drips to microdosing on LSD, psychedelics are shaking up the way we approach and treat mental health. A growing body of scientific evidence shows that these long-stigmatized substances could be potential antidepressants, alleviating symptoms by slipping into areas of the brain traditional SSRIs can’t reach, and encouraging new neural connections.

Despite these advances, psychedelics remain fairly mysterious. Researchers haven’t yet pinned down the various mechanisms through which they work inside our bodies. But now, they might be one step closer.

An international team of scientists led by the University of Helsinki in Finland believes they’ve struck biochemical gold. In a study published Monday in the journal Nature Neuroscience, the researchers found that psychedelics psilocin (the primary chemical in magic mushrooms) and LSD exert an antidepressant effect by binding to a protein, receptor tyrosine kinase beta (TrkB), which then activates brain-derived neurotrophic factor (BDNF), a protein that plays a crucial role in the growth, development, and maintenance of neurons; kind of like Miracle-Gro for the brain.

“I think [this study] is very exciting,” Greg Fonzo, co-director of the Center for Psychedelic Research and Therapy at The University of Texas at Austin’s Dell Medical School, who wasn’t involved in the study, tells Inverse. “It establishes a potential common mechanism for psychedelics along with other kinds of antidepressant treatments.” The researchers hope that this new information could potentially lead to creating more effective treatments for mental health disorders.

Keep reading

NEW RESEARCH REVEALS LSD’S MIND-ALTERING POWER TO ENHANCE LEARNING AND EXPLORATORY THINKING

Researchers report they have uncovered remarkable new effects of the potent psychedelic drug lysergic acid diethylamide (LSD) on human cognition, according to findings detailed in a new study. 

Published in Psychological Medicine, the study sheds light on LSD’s ability to accelerate learning when coupled with feedback and promote exploratory behavior. 

Researchers say the findings may hold the key to unraveling the enigmatic cognitive mechanisms that underlie the potential therapeutic benefits of LSD. 

Many recent studies have shown LSD-assisted psychotherapy to offer promising results in treating mental health conditions, including anxiety, depression, and post-traumatic stress disorder. 

Though LSD remains illegal in many countries when administered in a controlled setting under the guidance of a trained therapist, the psychedelic drug has shown the potential to enhance individuals’ capacity to explore and process challenging emotions and experiences. Studies have found that this process can often lead to profound insights and lasting breakthroughs in therapy.

Jonathan Kanen, the lead author of the study and a Gates Cambridge Scholar, postulates that the potential therapeutic effects of LSD may stem from the drug’s ability to foster new beneficial patterns of learning about the world by forming new mental associations. 

Keep reading

Celebrating The 80th Anniversary Of Bicycle Day: A Different Kind Of Trip

Every year, on April 19, an important anniversary rolls around that you may never have heard of. To those in the know, it’s called Bicycle Day, and it commemorates the first-ever intentional LSD trip. 

It all started when a Swiss chemist called Albert Hofmann had a very peculiar time while cycling home from the lab. Hofmann was the first person to synthesize LSD back in 1938. He did it by isolating chemical compounds found in a fungus called ergot, which infects grasses like rye and can have some profound effects on any humans unfortunate enough to accidentally consume it.

It’s safe to say that Hofmann didn’t think much of his discovery to begin with. What we now know as LSD was actually the 25th in a long line of similar compounds that he’d been experimenting with, and Hofmann’s research notes from the time reportedly reveal how no one was particularly enthused by it: “The new substance, however, aroused no special interest in our pharmacologists and physicians; testing was therefore discontinued.”

Keep reading

THE CIA’S APPALLING HUMAN EXPERIMENTS WITH MIND CONTROL

ON APRIL 10, 1953, ALLEN DULLES, THE NEWLY APPOINTED DIRECTOR OF THE CIA, delivered a speech to a gathering of Princeton alumni. Though the event was mundane, global tensions were running high. The Korean War was coming to an end, and earlier that week, The New York Times had published a startling story asserting that American POWs returning from the country may have been “converted” by “Communist brain-washers.”

Some GI’s were confessing to war crimes, like carrying out germ warfare against the Communists–a charge the U.S. categorically denied. Others were reportedly so brainwashed that they had refused to return to the United States at all. As if that weren’t enough, the U.S. was weeks away from secretly sponsoring the overthrow of a democratically elected leader in Iran.

Dulles had just become the first civilian director of an agency growing more powerful by the day, and the speech provided an early glimpse into his priorities for the CIA. “In the past few years we have become accustomed to hearing much about the battle for men’s minds–the war of ideologies,” he told the attendees. “I wonder, however, whether we clearly perceive the magnitude of the problem, whether we realize how sinister the battle for men’s minds has become in Soviet hands,” he continued. “We might call it, in its new form, ‘brain warfare.’”

Dulles proceeded to describe the “Soviet brain perversion techniques” as effective, but “abhorrent” and “nefarious.” He gestured to the American POWs returning from Korea, shells of the men they once were, parroting the Communist propaganda they had heard cycled for weeks on end. He expressed fears and uncertainty–were they using chemical agents? Hypnosis? Something else entirely? “We in the West,” the CIA Director conceded, “are somewhat handicapped in brain warfare.” This sort of non-consensual experiment, even on one’s enemies, was antithetical to American values, Dulles insisted, as well as antithetical to what should be human values.

Keep reading

The story of how the CIA conducted secret LSD experiments on unwitting US citizens

After World War II, the possibility of gaining control over a person’s mind became one of the top pursuits for intelligence services. Amid never-ending spy games, the capacity to make someone tell the full truth during an interrogation, or to wipe out a subject’s personality and impose another – perhaps, a controlled one – became quite attractive to secret services.

In 1979, former US State Department officer John Marks published a book called “The Search for the ‘Manchurian Candidate’,” which focused on the CIA’s mind-control experiments and is based on agency documents released under the Freedom of Information Act.

The term ‘Manchurian Candidate’ emerged from a title of a novel by Richard Condon, first published in 1959, which tells the story of a US soldier brainwashed and turned into an assassin by the Communists. Back then, the fear that America’s rivals might use such techniques was not only a fictional fantasy, but a matter of very serious concern.

This is how John Marks describes it: “In 1947 the National Security Act created not only the CIA but also the National Security Council – in sum, the command structure for the Cold War. Wartime [Office of Strategic Services] leaders like William Donovan and Allen Dulles lobbied feverishly for the Act. Officials within the new command structure soon put their fears and their grandiose notions to work. Reacting to the perceived threat, they adopted a ruthless and warlike posture toward anyone they considered an enemy – most especially the Soviet Union. They took it upon themselves to fight communism and things that might lead to communism everywhere in the world.”

Keep reading